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FGF4 is the earliest member of the fibroblast growth factor (FGF) family expressed during embryogenesis where it plays essential roles in
post-implantation development and limb growth and patterning. The expression of the Fgf4 gene in specific developmental stages, including
the ICM of the blastocyst, the myotomes, and the limb bud AER, is regulated by distinct enhancer elements (Hom) in the 3V UTR. We
previously identified the Hom3a region as the major DNA element responsible for Fgf4 expression in the myotomes and AER, and showed
that a conserved E-box is a target for the myogenic bHLH transcription factors MYF5 and MYOD. To further define the cis- and trans-acting
elements that determine Hom3a activity, we conducted a mutational analysis of the ability of the Hom3a region to drive lacZ expression in
the myotomes of transgenic mice. We identified a minimal enhancer of 226nt that contains four elements, including the E-box, necessary to
drive gene expression in the myotomes. One of these elements is a binding site for the GATA family of transcription factors, and we show
here that GATA 1–4 and 6 can synergize with MYF5 or MYOD to activate transcription of a reporter plasmid driven by a portion of the
Hom3a enhancer including the GATA site and the E-box. In line with this finding, we could show a direct interaction between MYF5/MYOD
and GATA-3 or GATA-4, mediated by the N-terminal and bHLH domains of MYF5/MYOD and the C-terminal zing finger domain of GATA-
3/4. To further study the role of the Hom3a enhancer in directing Fgf4 expression and the function of FGF4 in limb and muscle development,
we generated mutant mice in which the Fgf4 Hom3a region had been deleted (D3a). In situ hybridization analysis of sections from D3a/ D3a
embryos at E11.5 showed a drastically reduced expression of Fgf4 mRNA in the myotomes and AER. However, these mice developed
normally and show no limb or muscle defects, and the same was true of heterozygous mice in which one Fgf4 allele carried the Hom3a
deletion and the other was a null allele (D3a/Fgf4). Together, these results show that Hom3a is the major DNA enhancer element directing
Fgf4 expression in myotomes and limb bud AER, and that its activity in the myotomes results at least in part from the synergistic action of
GATA and bHLH myogenic factors that bind to evolutionary conserved sequences in the Hom3a enhancer. However, expression of Fgf4 in
the myotomes or AER of murine embryos does not appear to be essential for muscle or limb development.
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Fibroblast growth factors (FGFs) form a large family of
signaling molecules involved in early embryonic develop-
ment and organogenesis (Basilico and Moscatelli, 1992;
Goldfarb, 1996; Ornitz and Itoh, 2001). Among the FGFs,0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: basilc01@med.nyu.edu (C. Basilico).FGF4 is the earliest expressed FGF during embryogenesis
and has been shown to play an essential role in post-
implantation mouse development, and a less essential, but
important role in limb growth and patterning (Feldman et
al., 1995; Sun et al., 2002). FGF4 transcripts are first
detected in the ICM of the blastocyst at E4.5 and in
embryonal stem cells, and then in the primitive streak
(E7), branchial arches and myotomes (E9.5–13.5), the
apical ectodermal ridge (AER) of limb buds (E10.5–11.5)
and the tooth buds (E14.5) (Drucker and Goldfarb, 1993;
Niswander and Martin, 1992). At later stages of develop-
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ing silent in adult.
The mechanisms regulating expression of Fgf4 during
embryonic development have been the object of numerous
studies. We originally showed that expression of Fgf4 in EC
and ES cells, and thus presumably in the ICM of the
blastocyst, is determined by an enhancer element in the
3VUTR of the Fgf4 gene and that this enhancer element is
the target of the transcriptional regulators SOX2 and OCT-3,
which cooperatively bind to adjacent sequences in the EC
cell enhancer to synergistically activate transcription
(Ambrosetti et al., 1997; Dailey and Basilico, 2001; Yuan
et al., 1995). That SOX2 and OCT-3 are the major trans-
activators of Fgf4 in the ICM have been confirmed by in
vivo transgenic studies and by studies of Sox2 and Oct-3
knockout embryos (Avilion et al., 2002; Fraidenraich et al.,
1998; Nichols et al., 1998). The extension of these studies to
other stages of development showed that expression of Fgf4
in myotomes, limb bud AER, and tooth bud is also regulated
by 3V UTR enhancer elements that are distinct from those
driving Fgf4 expression in the blastocyst (Fraidenraich et
al., 1998). The Fgf4 3V UTR contains three conserved DNA
blocks, Hom 1, 2, and 3 (subdivided into 3a and 3b).
Hom3b corresponds to the previously mentioned EC cell
enhancer. Using a transgenic approach, we established that
the Hom3a region contains overlapping but distinct DNA
elements capable of driving lacZ expression in the myo-
tomes and AER of mouse embryos. Additional elements
contained within the Hom2 region were found to contribute
to Fgf4 expression in the rostral myotomes (Fraidenraich et
al., 1998, 2000). Interestingly, the same Hom2 region was
recently reported to direct Fgf4 expression in the tooth bud
(Kratochwil et al., 2002).
We also showed that the Hom3a element contains a
conserved E-box, and that this E-box is a target of myogenic
bHLH factors MYF5 and MYOD (Fraidenraich et al., 2000).
The analysis of Myf5 and MyoD knockout mice harboring
Fgf4-lacZ transgenes indicated that MYF5 is the physiolog-
ical transactivator of Fgf4 transcription in the myotomes, but
that MYOD could support expression of Fgf4 in the ventral
myotomes in the absence of MYF5 (Fraidenraich et al.,
2000). However, the expression of Fgf4 in these structures
must be regulated by additional factors, since MYF5 and
MYOD expression in the myotomes is much more wide-
spread than that of FGF4, that is restricted to a central portion
of the myotomes, and many tissues and cell lines express
MYF5 or MYOD but not FGF4 (Bober et al., 1991; Braun et
al., 1992, 1994; Fraidenraich et al., 2000).
In order to identify the cis- and trans-acting elements
which govern the myotomal expression of Fgf4, we have
now further dissected the functional elements within the
Hom3a region using mutational analysis. We show that
three additional regions, which comprise a putative GATA
factor binding site (Ko and Engel, 1993; Merika and Orkin,
1993), a putative binding site for the family of transcription
enhancer factors (TEFs) (Jacquemin et al., 1996; Kanekoand DePamphilis, 1998) and a sequence of unknown func-
tion, are required besides the E-box.
The GATA family of transcription factors includes six
members that have been shown to play critical roles in
regulating tissue-specific gene expression (Charron and
Nemer, 1999; Molkentin, 2000). We show that GATA
factors bind to a cognate site in the Hom3a enhancer, and
that they can synergize with MYF5 or MYOD to activate
transcription of a reporter plasmid driven by a portion of the
Fgf4 Hom3a enhancer. GATA-3 and -4 also interact with
MYF5 and MYOD in the absence of DNA.
Since Fgf4 null embryos do not develop past the im-
plantation stage (Feldman et al., 1995), the effect of FGF4
ablation at later stages of development has been difficult to
study. Thus, to further probe the role of the Hom3a enhancer
element in directing Fgf4 expression in the myotomes and
limb bud AER and the function of FGF4 in limb and muscle
development, we generated mice in which the Fgf4 Hom3a
region had been deleted. These mice developed beyond the
implantation stage and expressed very reduced amounts of
Fgf4 transcripts in the myotomes and AER, confirming that
Hom3a is the major myotomal/AER Fgf4 enhancer element.
However, these mice display no limb or muscle phenotype,
indicating that Fgf4 expression in these embryonic struc-
tures is not essential for their further development.Materials and methods
Plasmid DNAs
The pGNA-lacZ vector (Fraidenraich et al., 1998) was
used for the transient transgenesis experiments. The follow-
ing Fgf4 3V UTR regions were inserted downstream to the
lacZ gene, respectively; 3a Control (6251–6600), 3a1
(6251–6428), 3a2(6429–6600), 3a3(6251–6505), 3a4
(6336–6600), 3a5(6336–6505), 3a6(6280–6505), 3a7
(6308–6505). The nucleotides in the following 13 regions
of Fgf4 3VUTR were substitutionally mutated keeping the
length of nt 6251–6600, and inserted in the same site of the
lacZ construct; 3aMEF2(6508–6517), Mut1 (6291–6300),
Mut2 (6306–6317), Mut3 (6323–6332), Mut4 (6338–
6349), Mut5 (6367–6378), Mut6 (6384–6395), Mut7
(6401–6412), Mut8 (6418–6430), Mut9 (6436–6447),
Mut10 (6453–6464), Mut11 (6470–6481), Mut12 (6487–
6498). All the constructs derived from Fgf4 3VUTR were
made by PCR amplification.
cDNA of MyoD and Myf5 in the vector pCMVhygro
were gifts from M. Buckingham. For pull-down assay,
cDNAs of MyoD and Myf5 were amplified by PCR and
inserted to BamHI–EcoRI site of pGEX-2T, respectively
(Amersham Pharmacia Biotech). Mutated MyoD and Myf5
cDNAs were also made by PCR and inserted to the pGEX-
2T in the same way.
GATA cDNAs were kind gifts from these researchers:
GATA-1 and GATA-2, M. Yamamoto (University of Tsu-
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GATA-4, E. N. Olson (The University of Texas Southwest-
ern Medical Center); GATA-5 and GATA-6, S. Musco
(University of Pennsylvania) and R. Patient (University of
Nottingham, UK). GATA cDNAs were amplified by PCR
and inserted into pcDNA 3.1()/Myc-HisA vector (Invitro-
gen) and used for transient transfection to cells. For pull-
down assay, cDNAs of GATA-3 and GATA-4 and their
mutants were amplified by PCR and inserted downstream to
T7 polymerase binding site of pcDNA1 (Invitrogen).
To make the Fgf4-CAT constructs, Fgf4-CAT plasmid
derived from the pCAT3-Basic Vector (Promega) containing
the minimal murine Fgf4 promoter (nt 64 to nt 150) was
used (Ambrosetti et al., 2000). To generate constructs
pHom3a4xCAT (nt 6292–6305/6339–6366) oligonucleoti-
des containing the GATA binding site, TEF binding site and
E-box2 of Hom3a were multimerized and inserted upstream
to the Fgf4 promoter. The enhancers which have a mutated
GATA binding site and/or a mutated E-box2 were made in
the same way.
Transient transgenesis experiments
Standard microinjection of linearized DNA into the pro-
nucleus of fertilized eggs was performed at the NYU Trans-
genic Mouse Facility using Swiss Webster or FVB/N mouse.
X-gal staining of whole embryo was performed at E11.5 as
described previously (Fraidenraich et al., 1998). Incorpora-
tion of the transgene into the embryos was tested on yolk sac
DNA. At least five transgenic embryos were examined for X-
gal staining to define the construct as lacZ-negative.
Transfection and CAT assay
Calcium phosphate transfections were performed as
described previously (Curatola and Basilico, 1990). HeLa
cells were transfected with 2 Ag of DNA containing various
reporter plasmid; pHom3a4xCAT, no enhancer-CAT, GATA
mut-CAT, E-box mut-CAT, and GATA E-box mut-CATwith
or without 0.1 Ag of expression vectors; pcDNA 3.1()/
Myc–HisA-GATA-1, -2, -3, -4, -5, -6, and pCMVhygro-
MyoD, -Myf5. CMV-h-galactosidase (1 Ag) was used as
internal control. CAT activity was measured as described
previously (Curatola and Basilico, 1990).
Electrophoretic mobility shift assay
Whole cell extracts (WCE) were prepared from trans-
fected HeLa cells as previously described (Fraidenraich et
al., 2000). Oligonucleotides were labeled with [g-32P] ATP
and T4 polynucleotide kinase. Oligonucleotides used in
electrophoretic mobility shift assay are WT (5V-CACGTTC-
CAGCTATCTTTACCCAATG-3 V) and MUT (5 V-
GCTTCTCTTCCACATGTAGTATCTGG-3V). Binding
reactions contained 6 Ag of whole cell extract, 40 mM
Hepes, 4% Ficoll, 40 mM KCl, 0.05% NP40, 75 ng of poly(dI-dC) and approximately 30,000 cpm 32P-labeled probe
and 200-fold molar excess of competitor oligonucleotides
where appropriate. Protein binding was allowed to proceed
for 30 min at room temperature. The samples were imme-
diately loaded onto 4% polyacrylamide gels containing
0.5xTBE and ran at 20 mA at room temperature for 1.5 h.
Immunoblotting
Two hundred ninety-three cells were transfected by
pcDNA 3.1()/Myc-HisA-GATA-1, -2, -3, -4, -5, and -6,
respectively. WCE were prepared and loaded onto SDS-
PAGE and blotted into nitrocellulose membranes
(OSMONICS). Immunoblotting was performed using the
mAb 9E10 anti-human c-myc antibody (Roche) at 1:1000
dilution. The primary antibody was detected using anti-
mouse horseradish-peroxidase conjugated secondary anti-
body (Promega) in TBS containing 0.4% Tween20 and
ECL reagent as described by the manufacturer (Amersham
Pharmacia).
GST pull-down assay
All the GST fusion proteins were expressed in Escher-
ichia coli BL21 and purified by GST sepharose (Amersham
Pharmacia). Binding assay was performed with labeled
protein synthesized in vitro using rabbit reticulocyte lysate
system or wheat germ extract system (Promega) in the
presence of 35S-labeled methionine (Perkin Elmer) accord-
ing to the manufacturer’s protocol. Equal amounts of
immobilized GST fusion proteins were incubated overnight
at 4jC with 10 Al of 35S-labeled proteins in GST-binding
buffer containing 40 mM Hepes pH 7.2, 50 mM Na acetate
pH7.0, 200 mM NaCl, 2 mM EDTA, 5 mM dithiothreitol,
0.5% Nonidet P-40, protease inhibitors, and 2 Ag of bovine
serum albumin/ml. After five washes in GST binding buffer,
beads were boiled in SDS sample buffer to elute bound
protein, which was subsequently resolved by SDS-PAGE
and analyzed by autoradiography.
Generation of Hom3a knockout mice
To generateFgf4 Hom3a knockout mice, two fragments of
Fgf4 (5V arm; 3.7 kb-SphI–EcoRI fragment; nt 2446–6150,
3V arm; 1.8 kb-VspI–EcoNI fragment; nt 6509–8300) were
inserted into 5Vand 3V of the neor cassette of pKSloxPNT (a
gift from A. L. Joyner). The linearized plasmid was electro-
porated intoW4 embryonic stem cells. Transfected cells were
selected by G418 as previously described (Ortega et al.,
1998). Three G418 resistant homologous recombinant clones
were injected into C57BL/6 blastocysts. The chimeras were
crossed with CMV-Cre females to remove neor gene. The
heterozygote pups (D3a/+) were crossed with Fgf4 hetero-
zygotes (Fgf4+/) to generate D3a/Fgf4 mice. Heterozy-
gous Fgf4 knockout mice (Fgf4+/) were provided by V.E.
Papaioannou.
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The murine Fgf4 3V UTR (410 nt, including Hom2
region) and coding region (620 nt) were used to generate
33P-labeled RNA probes with T3 and T7 RNA polymerases,
12 AM cold UTP and 4 AM 33P-UTP. The hybridization
procedure was performed essentially as previously de-
scribed (Manova et al., 1990). Autoradiographic detection
was performed after 10 days of exposure. Slides were
counterstained with H&E.Fig. 1. (A) Structure of the murine Fgf4 gene and lacZ constructs used for
transgenic experiments. The Fgf4 gene has 3 exons whose coding
sequences are shown in black. In the 3V-untranslated region (3V-UTR), the
three regions of high homology between mouse and human are shown in
yellow rectangles (Hom1 nt 5310–5434, Hom2 nt 5705–5857, Hom3 nt
6260–6822). Hom3 is divided into 3a (nt 6260–6597) and 3b (nt 6597–
6822). The lacZ reporter gene was placed under the control of murine Fgf4
5V region (nt 2443–3693), as previously described (Fraidenraich et al.,
1998). (B) Seven deletion mutants of Hom3a region (3a1–7) and 13
nucleotide substitution mutants (3aMEF2, Mut1-12) were made and
inserted to the lacZ construct. The construct with mutation in the E-box
was previously described (Fraidenraich et al., 2000). Each of Mut1-12
mutants has a 10- to 13-bp substitution and together they span the entire 3a6
sequence. All the nucleotide substitution mutants were made within the
entire Hom3a sequence. lacZ expression results obtained from each
construct are listed on the right, +, lacZ-positive; , lacZ-negative in
myotomes of E11.5 embryos.Results
Four distinct DNA elements in Hom3a are required for the
expression of Fgf4 in the myotomes
By creating transgenic mice containing lacZ constructs
driven by different segments of the Fgf4 3VUTR and
analyzing embryo whole-mounts for h-galactosidase ex-
pression, we had previously identified the conserved Hom3a
region as the major enhancer element directing Fgf4 ex-
pression in the myotomes (Fig. 1A). A contribution of the
Hom2 region to expression in the rostral myotomes was also
observed, but transgenic constructs containing only the
Hom3a sequences (Fig. 1A) were fully capable of express-
ing lacZ in the trunk and tail myotomes (Fraidenraich et al.,
1998). Thus, to further define the cis-elements required for
Fgf4 expression in these structures, we concentrated our
analysis on the Hom3a region.
As previously shown, the Hom3a region contains a
conserved E-box (CAGCTG, nt 6356–6361) which repre-
sents the binding site for the myogenic factors MYOD and
MYF5, and is required for Fgf4 expression in the myo-
tomes (Fraidenraich et al., 2000). However, as discussed in
Introduction, transactivation by these factors appears to be
necessary, but not sufficient, to drive Fgf4 expression in the
myotomes. Thus, we conducted a deletion analysis of the
Hom3a enhancer using the same transient transgenic ap-
proach. Fig. 1B shows that a series of 5V and 3V deletions
identified a minimum Hom3a enhancer fragment of 226 bp
spanning nt 6280 to 6505 (construct 3a6, Fig. 1B) that was
still capable of eliciting strong lacZ expression in the
myotomes. The X-gal staining of myotomes driven by
these mutants was observed in the trunk and tail myotomes,
but not in the neck myotomes, that had been shown to
require the Hom2 region (Fig. 2) (Fraidenraich et al.,
1998).
To identify more precisely the cis-elements in Hom3a
relevant to myotome expression, we conducted a muta-
tional analysis of the minimal functional Hom3a fragment
3a6. We mutated 12 regions within 3a6; each mutant has a
10- to 13-bp substitution and together they span the entire
3a6 sequence (Fig. 1B). All 12 mutants (Mut 1–Mut 12)
were made in the context of the entire Hom3a sequence.
Mut 1, Mut 4, and Mut 10 abolished lacZ expression,indicating that at least four distinct cis-acting elements,
including the E-box 2, determine the activity of the Hom3a
enhancer.
We searched the TRANSFAC database for transcription
factor binding sites defined by Mut 1, Mut 4, and Mut 10,
and found that the mutated region of Mut 1 contains a
putative GATA factor binding site, 5V-AGATAG-3V (consen-
sus: 5V-(A/T)GATA(A/G)-3V) (Ko and Engel, 1993; Merika
and Orkin, 1993). There are two potential GATA binding
sites in the sequence of Hom3a: GATA-a (AGATAC) and
GATA-b (AGATAG) (Fig. 3). Mut 1 corresponds to the
GATA-b site. GATA-b completely conforms to the consen-
sus sequence, and is well conserved among species, while
the GATA-a site has one mismatch and lies outside of the
Fig. 2. Whole-mount X-gal staining of E11.5 embryos. Panel A shows an
embryo that harbors the 3a6 transgene, showing the X-gal staining in the
trunk and tail myotomes. Panel B shows an embryo harboring the transgene
Mut1, showing no X-gal staining in the myotomes.
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construct.
We also found that the mutated region of Mut 4 contains
a putative TEF protein binding site, 5V-AAATATGCA-3VFig. 3. Homology alignment of the Fgf4 Hom3a enhancer region of mouse, huma
mouse sequence. Two GATA binding sites (GATA-a, GATA-b), two E-boxes (E-bo
mutant and Mut1-12 mutants are shown in bold. Mutated nucleotides in Mut1, Mu
entries X14849 (mouse), J02986 (human), and AL929586.12 (zebrafish). The n
corresponding to the polarity of the zebrafish Fgf4 gene (Katoh, 2003).(consensus: 5V-(A/T)(A/G)(A/G)(A/T)ATG(C/T)N-3V) (Jac-
quemin et al., 1996). The mutated region of Mut 10 did not
match any known transcription factor-binding site in the
database. Interestingly, the 3V portion of Hom3a contains a
binding site for MEF2. (Black and Olson, 1998), a myo-
genic transcription factor that has been shown to interact
with GATA factors (Morin et al., 2000). However, mutation
of this MEF2 site had no effect on lacZ expression in
myotomes (Fig. 1B), in line with the finding that deletion
of 3V sequences containing the MEF2 site (constructs 3a3,
3a6, Fig. 1) did not impair lacZ expression.
All the GATA factors bind to the conserved GATA binding
site in Hom3a
The GATA family contains 6 factors (GATA-1–6) which
are divided into 2 subfamilies, GATA-1, -2, and -3 and
GATA-4, -5, and -6 (Charron and Nemer, 1999; Molkentin,
2000; Patient and McGhee, 2002). We performed EMSA to
determine whether GATA factor(s) could bind to the putative
GATA binding site (GATA-b). Each GATA factor was
transiently expressed in transfected 293 cells. Extracts from
these cells were incubated with a DNA probe containing
GATA-b. As shown in Fig. 4A, all GATA factors could bind
the probe. Binding was specifically competed in the presence
of excess unlabelled GATA-b DNA oligonucleotide, but not
in the presence of non-specific DNA oligonucleotide. 
 
n, and zebrafish. Shadowed nucleotides indicate identical nucleotides to the
x1, E-box2) and one MEF2 site are boxed. Mutated nucleotides in 3aMEF2
t4, and Mut 10 are shown in red. The sequences correspond to the Genbank
ucleotide numbers of the zebrafish sequences are in reverse orientation,
Fig. 4. All GATA factors bind to GATA-b site. (A) EMSA was performed
using GATA-b probe (5V-CACGTTCCAGCTATCTTTACCCAATG - 3V)
with whole cell extracts derived from 293 cells which had been transfected
with expression plasmids for GATA-1, lanes 1–3; GATA-2, lanes 4–6;
GATA-3, lanes 7–9; GATA-4, lanes 10–12; GATA-5, lanes 13–15;
GATA-6, lanes 16–18; pBluescript, lane 19. All the GATA factors
contained a Myc-His tag. A 200-fold excess of cold DNAs, wt (specific) or
(non-specific, 5V-GCTTCTCTTCCACATGTAGTATCTGG- 3V), were used
in competition assays. (B) Immunoblotting of transfected cell extracts was
performed using Anti-Myc antibody.
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the amount of probe bound varied significantly. Therefore,
we compared the expression levels of those factors using
Western analysis. Since all GATA proteins had been tagged
with Myc-His peptides, proteins from transfected cell
extracts were analyzed with an anti-c-Myc monoclonal
antibody. Even though all the GATA factors were cloned
within the same expression vector (pcDNA 3.1()/Myc-
HisA), each factor showed a different expression level (Fig.
4B). It is possible that variations in the stability of each of
the GATA proteins may be responsible for their different
levels of expression. No clear correlation between the
expression levels of those factors and their ability to bind
the DNA probe was evident, suggesting that these closely
related proteins have different affinities for the Hom3a
GATA-b site.
GATA factors and MYOD or MYF5 synergistically activate
the Fgf4 promoter
Because GATA factors have been shown to interact and
synergize with other proteins to activate transcription, we
investigated the possibility that GATA factors might sim-ilarly cooperate with MYOD or MYF5. We constructed a
reporter plasmid in which CAT gene expression was under
the control of the minimal murine Fgf4 promoter (Ambro-
setti et al., 2000) and four copies of the Hom3a region
spanning nucleotides 6292 to 6366. This plasmid was
transfected into HeLa cells alone or together with plasmids
expressing GATA factors and/or MYF5 or MYOD. While
reporter gene expression was not activated by GATA
proteins alone, expression of either MYOD or MYF5 alone
caused a significant induction of CAT gene expression. A
synergistic effect of GATA and Myf5 or MyoD cotransfec-
tion was observed, but the increase in CAT expression over
that produced by MYF5 or MYOD alone was only about
2-fold (data not shown). We considered the possibility that
some factor expressed by HeLa cells cooperated with
MYOD or MYF5 to drive gene transcription from this
plasmid and masked the synergy with GATA factors. Thus,
we created a new reporter plasmid in which the Hom3a
enhancer fragment contained a small deletion of 33 nucleo-
tides (nt 6306 to nt 6338), encompassing DNA sequences
that had been shown to be dispensable for Hom3a activity
(Figs. 1 and 3). The modified enhancer fragment still
contains the GATA binding site, TEF binding site, and E-
box (Fig. 5). This construct (pHom3a4xCAT) was trans-
fected into HeLa cells together with plasmids expressing
GATA factors and/or Myf5 or MyoD. Fig. 5A shows that
the pHom3a4xCAT plasmid had essentially no CAT activ-
ity in HeLa cells and that CAT expression was not
increased by cotransfection of Myf5-expressing plasmids
(or MyoD, not shown). Expression of GATA proteins 1–4
or -6 alone also did not stimulate CAT activity, but
cotransfection with Myf5 encoding plasmids resulted in a
strong synergistic activation of the CAT reporter plasmid.
GATA-5 increased CAT expression in the absence of Myf5,
but this effect appeared to be non-specific, as it was
produced also when we used a CAT reporter plasmid
lacking the Hom3a sequences (Fig. 5B). The synergistic
transactivation of the Hom3a4xCAT plasmid by GATA-1–
4 or -6 together with Myf5 or MyoD required the presence
of both protein binding sites in the Hom3a sequences since
mutation of either the GATA site or the E-box sequence
abolished activation (Fig. 5C). We quantitated the syner-
gistic activity of each GATA plasmid-MyoD/Myf5 combi-
nation using the formula (Fold induction by GATA +
MYF5 or MYOD) / ((Fold induction by GATA) + (Fold
induction by MYF5 or MYOD)) (Fig. 5D). Among all the
GATA factors, GATA-3 and GATA-4 showed the highest
synergism with MYF5 or MYOD.
GATA-3 and -4 interact with MYOD and with MYF5
We wished to determine the basis for the transcriptional
synergy observed between GATA factors and MYOD or
MYF5. We first assessed cooperative binding of GATA
proteins and MYOD or MYF5 by using a DNA probe
corresponding to the sequence used to show synergistic
Fig. 5. GATA factors and MYF5 (or MYOD) synergistically activate the expression of a reporter plasmid driven by the Hom3a region. The pHom3a4xCAT
reporter plasmids were transfected into HeLa cells together with CMV promoter-driven plasmids expressing GATA-1–6 proteins, MYF5 or MYOD as
described in Materials and methods. A schematic representation of the pHom3axCAT plasmid and mutated derivatives is shown on the right. Fold increase
is the level of CAT expression over that observed by transfecting the pHom3a4xCAT plasmid alone. The reporter plasmids used were (A) pHom3a4xCAT,
(B) the same plasmid devoid of Hom3a sequences, and (C) modified pHom3axCAT plasmids containing base substitution mutations in the GATA binding
site (AGATAG replaced by ATCGCG) or E-box (CAGCTG replaced by CCTAGG). Abbreviations: P, Fgf4 promoter; CAT, chloramphenical acetyl
transferase.
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in EMSAs. However, we could not detect a ternary complex
formed by these two proteins with the DNA probe, either
because they do not bind cooperatively, or the affinity oftheir interaction is low. Next, we examined whether MYF5
(or MYOD) can directly interact with GATA-3 or -4 in the
absence of DNA using GST pull-down assays. We chose
GATA-3 and -4 since they exhibited the highest degrees of
A. Iwahori et al. / Developmental Biology 270 (2004) 525–537532synergism with MYF5 or MYOD in activating the Hom3a
reporter plasmid. Furthermore, GATA-3 has been shown to
be expressed in the somites (George et al., 1994). MyoD or
Myf5 was expressed as GST-fusion proteins in bacteria.
GATA-3 or GATA-4 was produced by in vitro translation
using 35S-labeled methionine. GST-MYOD or GST-MYF5,
but not GST alone, was able to pull down 35S-labeled
GATA-3 or GATA-4 (Fig. 6B). These interactions were
not affected by inclusion of up to 400 Ag of ethidium
bromide per ml, indicating that true protein–protein inter-
actions were detected (Fig. 6C).Fig. 6. GATA-3 and -4 interact with MYF5 and MYOD in the absence of DNA.
assay. The two zinc finger domains (Nf, Cf) of GATA-3 and the bHLH domain of
alanines substituted for cysteines at aa263, 266 (Nf) and 317, 320 (Cf), resp
corresponds to the second a-helix of the bHLH structure. The regions mutated by
immobilized, bacterially produced GST-fusion proteins (GST-MYOD and GST-MY
vitro translation. After incubation, the protein complexes were centrifuged, extens
were visualized by autoradiography. (C) The samples were treated as above except
where indicated. (D) Mapping of GATA-3 domains required for the interaction
incubated with GST-MYOD WT. (E) Mapping of GATA-3 C-terminal region requ
with MYOD WT. (F) Mapping of MYOD domains required for the interaction with
MYOD, or GST fusion proteins containing the N terminal (N-ter), C terminal (C-t
the text. MYOD c-ter did not interact with GATA-3. (G) Mapping of MYOD N-term
domain. G3 zinc was incubated with GST fusion proteins of the MYOD N termina
ter, N-terminal domain; C-ter, C-terminal domain; Nf-mut, N-terminal zinc finger d
finger domain; C-end, C-terminal fragment; bHLH, bHLH domain; bHLH mut, bTo identify the protein domains which mediate these
interactions, deletion mutants or substitutional mutants of
GATA-3, MYOD, and MYF5 were tested (Figs. 6D–G).
GATA-3 was divided into two regions, the N-terminal
region containing the N-terminal zinc finger (G3 N-ter)
and the C-terminal region containing the C-terminal zinc
finger (G3 C-ter). The G3 C-ter mutant bound wild type
MYOD, while the G3 N-ter mutant did not (Fig. 6D). Since
the zinc finger domains of GATA factors are well conserved,
we produced mutants which had amino acid substitutions in
the N- or C-terminal zinc fingers to determine whether they(A) Constructs of GATA-3 and -4, MYOD and MYF5 used for pull-down
MYOD are shadowed. The constructs G3 Nf mut and G3 Cf mut have two
ectively. MYOD bHLHmut has AAAAA substituted for KVEIL, which
substitution are indicated by X. (B) Pull-down assay was performed using
F5) and 35S-labeled wild type GATA-3 or GATA-4 proteins produced by in
ively washed and separated on a 10% SDS-PAGE. Bound-labeled proteins
that binding and wash buffers contained 400 Ag of ethidium bromide per ml
with MYOD. GATA-3 WT, N-ter, C-ter, Nf-mut, or Cf-mut proteins were
ired for the interaction with MYOD. G3 zinc or G3 C-end were incubated
GATA-3. Full-length GATA-3 protein was incubated with full-length GST-
er) or bHLH domains, or mutated bHLH portions of MYOD as described in
inal and bHLH region required for the interaction with GATA-3 zinc finger
l (N-ter) or bHLH peptides. Abbreviations: G3, GATA-3; WT, wild type; N-
omain mutation; Cf-mut, C-terminal zinc finger domain mutation; zinc, zinc
HLH domain mutation.
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constructs, two cysteins were replaced by two alanines
which causes a collapse of the zinc finger structure. Inter-
estingly, both the G3 Nf-mut and G3 Cf-mut were able to
bind to wild type MYOD (Fig. 6D). Furthermore, two
deletion mutants, G3 zinc and G3 C-end, were tested to
map the binding site in the C-terminal region (Fig. 6E). The
G3 zinc mutant bound to MYOD, but G3 C-end did not.
We then tested various MYOD mutants (Fig. 6F).
MYOD was divided into three parts, N-terminal, bHLH
domain, and C-terminal region. The N-terminal region and
the bHLH domain bound to wild type GATA-3, but the
C-terminal region did not. A five amino acid mutation in
the second helix of the bHLH domain did not affect the
binding to wild type GATA-3. Finally, we determined
whether the GATA-3 zinc finger domain could interact
with the N-terminal or bHLH regions of MYOD. Fig. 6G
shows that the N-terminal region of MYOD bound to the
GATA-3 zinc finger domain and that a weak interaction
could also be detected with the bHLH domain. The
MYF5 mutants showed similar results (data not shown).
Together, these experiments demonstrate a direct protein–
protein interaction between GATA-3/4 with MYOD or
MYF5 in the absence of DNA. This interaction is
mediated by the GATA-3/4 C-terminal zinc finger domain
and by the N-terminal portion and bHLH domain of
MYOD/MYF5.Fig. 7. (A) Strategy for construction of the Hom3a mutant allele. The Fgf4 wild ty
sequences used as a probe for southern blot analysis. E and B represent EcoRI an
gene targetting in ES cells contains a neomycin resistance cassette (neor ) flanked b
crossing Fgf4 neoD3a and CMV-Cre mice, resulting in the Fgf4D3a allele. (B) Geno
null (D3a/D3a) mice by southern blot analysis. Genomic DNAs from tails were
indicated 32p-labeled probe. Positions of DNA molecular size standards are shown
allele yields a 4.0-kb DNA fragment, and the D3a allele a 1.7-kb DNA fragment. (C
panel) and PCR (right panel). The FGF4 null allele contains a neor gene inserted
Intron 1R-(5V-GCTCATCTCCTGTCTACCGGTG-3V) were used for PCR to identif
Hom3a null allele (1.7 kb) by Southern blot analysis on the left panel, but only
Positions of DNA size standards are shown at the left and right (kb).Targeted deletion of Hom3a results in reduced expression of
Fgf4 in the myotomes and AER, but does not cause a muscle
or limb phenotype
We have shown that the Fgf4 Hom3a region drives the
expression of lacZ in the myotomes and limb bud AER in
transgenic mice. We wished to verify further the role of
Hom3a in Fgf4 gene expression by assessing whether a
deletion of Hom3a in the endogenous Fgf4 gene would
abolish or reduce Fgf4 expression in the myotomes and
AER, and also to determine whether suppression of Fgf4
expression in these structures would affect limb or muscle
development. We took advantage of the existence of distinct
enhancer elements within the Fgf4 3VUTR, where the
Hom3b element is required for expression in the ICM of
the blastocyst and Hom3a for expression in the myotomes
and AER (Fraidenraich et al., 1998). We reasoned that mice
with only a deletion of the Hom3a element would not
display early embryonic lethality and thus allow us to assess
the effect of this mutation on limb and muscle development.
The targeting vector was designed to produce a mutated
Fgf4 allele in which the Hom3a element (358 bp, nt 6151 to
nt 6508) could be deleted after homologous recombination.
Hom3a was replaced with the neor gene flanked by loxP
sites (Fig. 7A). The targeting vector was electroporated into
W4-ES cells, and two clones of targeted ES cells were
injected into C57BL/6 blastocysts.pe allele is shown at the top (see also Fig. 1). The bar represents the DNA
d BamHI restriction sites, respectively. The Fgf4 neoD3a allele produced by
y two loxP sites (triangles). Removal of the neor sequences was achieved by
typing of wild type (+/+), heterozygotes (neoD3a/+), (D3a/+) and Hom3a
digested with EcoRI, and Southern blot analysis was performed with the
to the left (kb). The wild-type allele yields a 1.9-kb DNA fragment, the neor
) Genotyping of D3a/Fgf4 and D3a/+ mice by Southern blot analysis (left
in the first exon. Primers NeoF- (5V-CTCGTGCTTTACGGTATCG-3V) and
y the neor transgene. Both genotypes show the wild type allele (1.9 kb) and
D3a/Fgf4 shows the neor transgene detected by PCR on the right panel.
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neor gene, male chimeras were crossed with CMV-Cre
transgenic mice. By excising the neor gene by Cre-loxP
recombination, heterozygotes (D3a/+) were born and de-
veloped normally, and we could obtain homozygotes (D3a/
D3a) by crossing these heterozygotes (Fig. 7B). These mice
appeared normal and had no detectable limb or muscle
defects. Immunohistochemistry of myotome sections of
E11.5 and E13.5 embryos using anti-Desmin antibodies
revealed no differences in the appearance of this muscle-
specific marker between wild type and D3a/D3a embryos
(data not shown).
We performed in situ hybridization using Fgf4 ribop-
robes on sections from heterozygous (D3a/+) and homozy-
gous embryos (D3a/D3a) at E11.5. Fgf4 transcripts could be
easily detected in both the AER and myotomes of D3a/+
and wild type embryos (Fig. 8 and data not shown), but
were strikingly reduced, although not completely absent in
D3a/D3a embryos. We estimated the level of expression of
Fgf4 mRNA of D3a/D3a embryos to be about 20% that of
D3a/+ embryos, a result that would predict expression from
a single D3a Fgf4 allele to be about 10% of the wild type.
While this strongly reduced level of expression confirms the
hypothesis that Hom3a is the major enhancer element
responsible for Fgf4 expression in myotomes and the
AER (see Discussion), it was possible that this low levelFig. 8. Fgf4 expression is drastically reduced in the myotomes and AER of D3a em
using 33P-labeled Fgf4 antisense probes. D3a/+ mice were intercrossed to generat
with Fgf4+/ mice to generate D3a/Fgf4 embryos. All the embryos except D3a/F
embryos was slightly higher than that of D3a/+ (not shown). The experiment w
methods). Numerous sections from 2 to 3 embryos for each genotype were examin
each genotype. The data shown are representative of the average signal intensity
similar results. Abbreviations: nt, neural tube; d, dorsal; v, ventral.of expression was sufficient for FGF4 to perform its
function in these structures. To reduce this level of expres-
sion even further, we crossed our D3a mice with heterozy-
gous Fgf4 knockout mice (Feldman et al., 1995) to obtain
D3a/Fgf4 embryos. These animals also escaped early post-
implantation lethality and did not show any apparent limb or
muscle defects. Together, these experiments indicate that
expression of Fgf4 in the myotomes and AER is not
essential for limb or muscle development.Discussion
The experiments presented in this report were designed
to increase our understanding of the mechanisms regulating
expression of Fgf4 in the myotomes and further determine
whether Fgf4’s expression in these embryonic structures
plays a role in muscle development. Previous results had
identified a conserved 3Venhancer (Hom3a) in the Fgf4 gene
as the major DNA element responsible for Fgf4 expression
in the myotomes and AER, and indicated that the myotome
and AER enhancers are overlapping, but distinct. Further-
more, the myogenic transcription factors MYF5 and MYOD
had been shown to play a role in FGF4 expression in the
myotomes by targeting a conserved E-box in Hom3A
(Fraidenraich et al., 1998, 2000). By conducting a muta-bryos. In situ hybridization was performed on sections from E11.5 embryos
e +/+ (wild type), D3a/+, and D3a/D3a embryos. D3a/+ mice were crossed
gf4 are from the same litter. The Fgf4 RNA expression level of wild type
as performed in triplicate using different Fgf4 probes (see Materials and
ed. There was some variability in signal intensity from section to section in
in these embryos. Analysis of tissue sections of E10.5 embryos produced
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lacZ expression in the myotomes of transgenic mice, we
identified three additional DNA regions that are required for
Hom3a activity. Because one of these regions contains a
consensus GATA binding site that is perfectly conserved in
murine, human, and zebrafish DNA, we examined the
possibility that GATA factors cooperate with MYF5, or
MYOD, to direct expression of Fgf4 in the myotomes.
The GATA family of transcription factors includes six
members, subdivided into two subfamilies (1–3 and 4–6)
from sequence homology and expression patterns (Charron
and Nemer, 1999; Molkentin, 2000; Patient and McGhee,
2002). They contain a highly conserved DNA binding
domain consisting of two zinc fingers with a Cys-X2-Cys-
X17-Cys-X2-Cys motif that directs binding to the target
DNA sequence (A/T)GATA(A/G). GATA-1–3 are predom-
inantly expressed in hematopoietic stem cells, but also in
other tissues. GATA-4–6 are expressed in various meso-
derm- and endoderm-derived tissues, notably in the heart,
where GATA-4 plays an important developmental role.
Although it would have been desirable to identify all
transcription factors contributing to Fgf4 expression in the
myotomes, the lack of a tissue culture system, which is
equivalent to myotomes, rendered this complete analysis
extremely difficult. Thus, we concentrated our efforts on the
GATA factors, as these factors are known to interact and
synergize with other transcription factors in promoting
transcription of target genes (Anderson et al., 1998; Blokzijl
et al., 2002; Dai et al., 2002; Durocher et al., 1997; Morin et
al., 2000; Murakami et al., 1999; Wadman et al., 1997).
After showing that all GATA factors can bind the
conserved GATA site in the Fgf4 Hom3a region, we tested
the ability of GATA proteins to synergize with MYF5 and
MYOD using a reporter plasmid containing a portion of
the Hom3a sequence which included the conserved GATA
site and E-box. GATA factors or MYF5 (or MYOD) alone
had no effect on the activity of this reporter plasmid, with
the exception of GATA-5, whose transactivating effect,
however, appeared non-specific as it was detected also in
a plasmid lacking the Hom3a enhancer. On the other
hand, all other GATA factors showed a robust synergistic
effect with MYF5 or MYOD that required both the GATA
and bHLH binding sites. Thus, GATA factors can syner-
gize with myogenic bHLH factors to promote gene
expression.
To identify the mechanisms responsible for this syner-
gism, we concentrated on GATA-3 and -4, which showed
the highest degree of synergism with bHLH myogenic
factors. Furthermore, GATA-3 has been shown to be
expressed in the somites at E10, and its promoter can drive
lacZ expression in the same structures at E11.5 (George et
al., 1994). Although we did not detect cooperative binding
of these proteins to DNA using EMSAs, we could demon-
strate a direct protein–protein interaction between GATA-3
or GATA-4 with MYF5 or MYOD, using pull-down experi-
ments and mapped the major site of contact to the C-terminal zinc finger-containing domain of GATA-3, and
the N-terminal and bHLH portion of MYOD.
GATA proteins have been shown to interact and syner-
gize with other transcription factors to promote transcription
of target genes. Interestingly, GATA-4 has been shown to
interact with two other myogenic factors, MEF2 and d-Hand
(Dai et al., 2002; Morin et al., 2000). The MEF2 binding
site does not appear to be essential for Fgf4 expression in
the myotomes but interestingly, d-Hand is a bHLH factor,
similar to MYOD and MYF5, and shares with these factors
the ability to bind E-box DNA. The ability of GATA-3 and -
4 to interact with MYOD maps to the same C-terminal
domain, which has been shown to interact with d-Hand.
However, unlike the GATA/d-Hand synergism, that between
GATA proteins and MYOD/MYF5 requires that both pro-
teins bind to their target DNA sequences. Thus, the ability
of GATA proteins to interact with specific bHLH factors
may be a property which is conserved in evolution.
The regulation of Fgf4 expression in the myotomes is
clearly complex since its major regulatory element, Hom3a,
contains at least four DNA regions, which are necessary for
gene expression. We have shown that both a conserved E-
box and conserved GATA protein binding site play impor-
tant roles in regulating the expression of the Fgf4 gene in
this embryonic structure. Since mutations in additional
transcription factor binding sites abolish Hom3a’s ability
to drive gene expression in the myotomes, MYF5/MYOD
and GATA factors are probably necessary but not sufficient
to promote Fgf4 expression there and may cooperate with
other factors that remain to be identified.
A further purpose of this work was to assess whether
expression of Fgf4 in the myotomes and AER was impor-
tant for limb and muscle development. We reasoned that if
the Hom3a element was the major element directing Fgf4
expression in these structures, its deletion would selectively
abolish Fgf4 expression in the myotomes and AER. Since
Fgf4 expression in the ICM of the blastocyst depends on the
Hom3b element (Fraidenraich et al., 1998), knockout of the
Hom3a enhancer should not have affected blastocyst ex-
pression of Fgf4 or early development, and thus obviate the
early lethality exhibited by Fgf4 null embryos. This strategy
presents some advantages over the conditional gene knock-
out approach, utilizing tissue-specific Cre-loxP-mediated
recombination, in that deletion of the enhancer element is
present in the embryos from day 0, thus obviating the
problem of obtaining expression of the Cre recombinase
in the targeted tissues in a very precise temporal and spatial
manner, as well as the possibility that the targeted gene may
not be disrupted by the recombination event in every cell.
We succeeded in obtaining mice with an homozygous
deletion of the Hom3a enhancer. Expression of Fgf4 RNA
in the myotomes and AER was strongly reduced but not
totally abolished. While the Hom3a region had been shown
to be essential for lacZ expression in these structures in
transgenic mice, using a vector that comprised 1.2 kb of 5V
sequences and more than 2 kb of sequences 3V to the coding
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possibility that more distant elements contribute to Fgf4
expression in the AER and myotomes. Furthermore, we
have previously observed that the Hom2 region plays a role
in Fgf4 expression in rostral myotomes (Fraidenraich et al.,
1998). The same Hom2 Fgf4 region has recently been
shown to be target for LEF-1/Wnt signaling in the tooth
bud (Kratochwil et al., 2002). Wnt signaling is known to be
active in the AER (Barrow et al., 2003; Capdevila and
Izpisua Belmonte, 2001; Kawakami et al., 2001; Kengaku et
al., 1998), and possibly the myotomes, and thus activation
of gene expression through Hom2 could be responsible for
the low residual expression of Fgf4 mRNA in the AER and
myotomes of Hom3a mutant mice. Irrespective of the
mechanisms driving residual expression of Fgf4 mRNA in
these structures, the strong reduction of Fgf4 expression in
the myotomes and AER of Hom3a mutant embryos con-
firms the hypothesis that the Hom3a enhancer is the major
cis-element driving Fgf4 expression there. These results are
in contrast to a report by Moon et al. (2000), that suggested
that the major regulatory elements controlling Fgf4 expres-
sion during embryogenesis were located 5V of the coding
sequences, but in line with previous results from our and
other laboratories indicating that Fgf4 expression is mainly
regulated by enhancer elements in the 3V UTR (Ambrosetti
et al., 1997; Curatola and Basilico, 1990; Dailey and
Basilico, 2001; Kratochwil et al., 2002; Luster et al.,
2000; Nowling et al., 2003).
We did not, however, observe any limb or muscle
development defect in the Hom3a mutant mice. Since it
was possible that the residual levels of expression of Fgf4
in the myotomes and AER of these embryos could have
been sufficient to fulfill its function, we sought to reduce
this level of expression even further by crossing our D3a
mice with Fgf4+/ mice to obtain D3a/Fgf4 embryos.
This should have reduced the level of expression of Fgf4 to
less than 10% of the wild type. However, again, these
animals were born with no apparent limb or muscle
defects. We believe it is unlikely that the almost undetect-
able levels of expression of Fgf4 in the myotomes and
AER of these embryos would have been sufficient to
maintain FGF4 function. Indeed, other investigators have
shown that transient, reduced Fgf4 expression can lead to a
limb phenotype (Sun et al., 2002). Thus, the most plausible
explanation for our results is that Fgf4 expression is not
essential for limb and muscle development, probably be-
cause of functional redundancy and compensation by other
FGFs expressed in these structures. Indeed, these experi-
ments confirm the conclusions of the elegant work of Sun
et al. (2002), which showed that inactivation of FGF4
alone in the AER by Cre-driven recombination had no
effect on limb development, but considerably worsened the
limb phenotype observed in embryos following FGF8
inactivation. It is likely that the situation in the somitic
myotomes is similar. Other FGFs, notably FGF5 and
FGF6, are expressed in myotomes (Han and Martin, 1993;Haub and Goldfarb, 1991), probably providing a redundant
function with FGF4. Knockout of the Fgf5 or the Fgf6 genes
does not affect muscle development (Floss et al., 1997;
Hebert et al., 1994), but inactivation of FGF4 together with
FGF5 and FGF6 may reveal a function for FGF signaling in
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